The vulnerable ventral tegmental area in Parkinson’s disease
Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that causes motor disabilities and cognitive dysfunction due to the degeneration and loss of dopaminergic neurons in the midbrain. There is no debate as to whether the loss of neurons in the substantia nigra pars compacta (SNpc) is directly causative of the motor symptoms of PD [1]. While the ventral tegmental area (VTA) has long been suggested to be involved in PD [2], some authors have stated that the VTA is relatively spared [3], [4], [5], [6] and some textbooks of neurology, neuroscience, and movement disorders state that the VTA is “affected little or not at all” [7], [8]. Our motivation for this study was to review the existing literature and investigate the degree to which the VTA is involved in PD.
Previous research has provided several theories explaining this relative sparing, such as the variety of neurons found in the VTA [3], [4], lower expression of the dopamine transporter [5], differences in calcium channel expression, as well as in levels of cytosolic dopamine and the presence of α-synuclein [6], [9]. Here, we conduct a review of eight previous neuropathological studies in humans that directly quantified dopamine neurons in both the SNpc and VTA and add three new PD cases to the literature. We conclude, unequivocally, that the VTA degenerates in PD. This information could be helpful in understanding the pathophysiology of non-motor symptoms of PD. This line of evidence is consistent with widespread degeneration of ascending projection systems in PD including cholinergic, noradrenergic, serotonergic, and dopaminergic nuclei [10].
The VTA extends laterally from the midline (0 mm) to 4 mm and from 4 mm caudal to the mammillary bodies to 9 mm [11]. It contains dopamine neurons that project mainly to the ventral striatum and prefrontal cortex, with some projections to the amygdala. The VTA integrates information from a variety of cortical, brainstem, and peripheral centers, and contains a diversity of dopaminergic, GABAergic, and glutamatergic neurons, while the SNpc does not express glutamatergic neurons [3], [4], [12], [13]. Due to the diversity of neurons, the VTA responds to local and distant neuromodulators [5]. The VTA has been implicated in a variety of behaviors and psychopathological states, including depression, anxiety, drug addiction, feeding, reward processing, and executive function [14]. Crucially, many PD patients have non-motor symptoms that include disorders associated with the VTA. For instance, 25% of PD patients have anxiety and/or depression [15] and nearly 30% of PD patients have executive dysfunction [16]. We present evidence from 43 previous PD cases and three new ones to explicitly test the hypothesis that the VTA is extensively involved in PD.
Section snippets
Literature review
The following key words were used to collect published journal articles on the degeneration of the VTA in PD: ventral tegmental area; Parkinson’s disease; dopamine; and degeneration. The articles were then analyzed for content of dopaminergic degeneration in the VTA and SNpc.
Collection
Seven perfusion-fixed (4% formaldehyde) human midbrains (from superior colliculus to cerebral peduncles) were collected. Brain blocks were post-fixed for at least one week in formaldehyde. For cryoprotection, midbrains were
Results
We reviewed eight studies in which TH expression was quantified in the VTA and SNpc. Though all of the previous studies reported here aimed to quantify TH differences between PD and controls, not all used the same methods. For instance, most studies used haematoxylin–eosin staining to label neuromelanin [11], [21], [22], which Bogerts had established as an appropriate marker for catecholaminergic neurons [23]. One study only characterized pigmented neurons [20], another used immunostaining for
Discussion
We report that both in previous literature and in our new data, the VTA consistently degenerates in PD. Our new cases indicate a 49 percent decrease, on average, of TH-positive cells (Table 1), which falls in the 40–77 percent range reported in previous studies [21], [26]. These data clearly and unequivocally establish that the VTA is involved in PD. We used TH as a marker of dopamine neurons; however, it should be noted that this enzyme is also found in other catecholaminergic neurons.
Acknowledgments
The authors thank the donors and their families. This study was funded by the University of Iowa Pharmacological Sciences Training Grant (5T32GM067795-11) and Dr. Narayanan’s R01 (NS089470). These funding sources did not partake in study design, data collection and analysis, or the drafting and submission of this manuscript.
References (55)
- et al.
Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat
Neuroscience
(2008) - et al.
Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system
Neuron
(2008) - et al.
Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons
Neuron
(2009) - et al.
Metabolic hormones, dopamine circuits, and feeding
Front. Neuroendocrinol.
(2010) - et al.
Two neurotropic viruses, herpes simplex virus type 1 and mouse hepatitis virus, spread along different neural pathways from the main olfactory bulb
Neuroscience
(1993) - et al.
Distribution of dopaminergic fibers in the central division of the extended amygdala of the rat
Brain Res.
(1994) - et al.
Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson’s disease and Huntington’s chorea
Neuroscience
(1988) - et al.
Frontal-lobe syndrome and psychosis after damage to the brainstem dopaminergic nuclei
J. Neurol. Sci.
(2007) - et al.
Prefrontal D1 dopamine signaling is necessary for temporal expectation during reaction time performance
Neuroscience
(2013) - et al.
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease
Brain Res.
(1983)
Age-dependent decline in human brain dopamine D1 and D2 receptors
Brain Res.
Decreased plasma membrane expression of striatal dopamine transporter in aging
Neurobiol. Aging
Staging of brain pathology related to sporadic Parkinson’s disease
Neurobiol. Aging
A review of Parkinson’s disease
Br. Med. Bull.
Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway
Mol. Chem. Neuropathol. Spons. Int. Soc. Neurochem. World Fed. Neurol. Res. Groups Neurochem. Cerebrospinal Fluid
Vglut2 afferents to the medial prefrontal and primary somatosensory cortices: a combined retrograde tracing in situ hybridization study [corrected]
J. Comp. Neurol.
Adams and Victor’s Principles of Neurology
Marsden’s Book of Movement Disorders
Calbindin controls release probability in ventral tegmental area dopamine neurons
Nat. Neurosci.
Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease
Rev. Neurosci.
Midbrain dopaminergic cell loss in Parkinson’s disease: computer visualization
Ann. Neurol.
Distribution of GABA-T-intensive neurons in the rat forebrain and midbrain
J. Comp. Neurol.
Widespread origin of the primate mesofrontal dopamine system
Cereb. Cortex
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis
Neurology
Cognitive function in early Parkinsonös disease: a population-based study
Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc.
The vascular supply of the functional compartments of the human striatum
Brain
Parkinson’s disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions
Neurology
Cited by (112)
Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer's and Parkinson's disease
2024, Frontiers in NeuroendocrinologyA mouse model of sleep disorders in Parkinson's disease showing distinct effects of dopamine D2-like receptor activation
2023, Progress in NeurobiologyThe role of dopamine in NLRP3 inflammasome inhibition: Implications for neurodegenerative diseases
2023, Ageing Research ReviewsNovel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice
2023, Journal of Pharmacological SciencesParaquat exposure produces sex-dependent reduction in binge-like alcohol drinking in high alcohol-preferring mice
2023, Food and Chemical Toxicology